High Rates of Non-Response Across Treatment Attempts in Chronic Irritable Bowel Syndrome: Results From a Follow-Up Study in Tertiary Care

Yuanjun Dong*, David Baumeister, Sabrina Berens, Wolfgang Eich and Jonas Tesarz

Department of General Internal Medicine and Psychosomatics, University Hospital Heidelberg, Heidelberg, Germany

Objective: Despite a wealth of treatment options for irritable bowel syndrome (IBS), data on the subjective experience of treatments in ongoing clinical practice are sparse. This follow-up study assessed the individual usage of treatment modalities by IBS patients over time and investigated the patients’ subjective experience of therapeutic impact.

Methods: The study was conducted at the Specialty Clinic for Functional Gastrointestinal Disorders of the Heidelberg University Hospital. All patients who fulfilled the Rome III criteria for IBS and treated in our outpatient clinic between January 2012 and December 2016 were invited to the assessment. The primary outcome variables were individual usage of treatment modalities and the Patient Global Impression of Change (PGIC) with treatments.

Results: Three hundred and sixty-six patients fulfilled the Rome III criteria for IBS and thus were eligible for this study. Two hundred and seven patients dropped out from the study. The study could include 159 patients (43.7 ± 17.1 years; 71.1% female). The mean time since the first visit to the clinic was 2.8 ± 1.3 years (median 3.0 years). The mean time of symptom duration was 14.1 ± 11.1 years (median 10 years). The average number of treatment attempts was 12, ranging from 2 to 39). With respect to the subjective experience of therapeutic impact, there were no significant differences in the PGIC scores among different treatments (p = 0.183). The rates of non-response rates (minimally improved, no change, or minimally worse) ranged from 63.0% to 83.9%. The PGIC score was correlated negatively with the mean number of treatment attempts (r = −0.316, p < 0.01). The mean number of treatment attempts was correlated negatively with quality of life (r = −0.262, p < 0.01).

Conclusion: A multidisciplinary treatment approach of IBS is characterized by high rates of non-response and a high number of frustrating treatment attempts. The connection between the various treatment attempts and the frustrating subjective experience of therapeutic impact puts a substantial burden on IBS patients.

Keywords: irritable bowel syndrome, treatment modalities, subjective experience, therapeutic impact, response rate
INTRODUCTION

Irritable bowel syndrome (IBS) is a distressing chronic gastrointestinal disorder characterized by abdominal pain and changes in bowel habits (1). With a global prevalence of 9% to 12%, IBS is one of the most common functional gastrointestinal disorders in the world (2) and is associated with a substantial socioeconomic impact on the individual (3) as well as on society (4, 5). As the exact origin of IBS remains poorly understood, there are neither causal therapeutic approaches nor single-treatment interventions suitable and effective for all patients (6, 7). Accordingly, guidelines for the diagnosis and treatment of functional gastrointestinal disorders emphasize the combination of different therapies in a multimodal interdisciplinary treatment approach (8), including non-specific therapeutic recommendations (e.g., physical activity) as well as more specific recommendations, such as dietary advices, psychological interventions, and symptom-targeting medications. Although current guidelines (9) included a variety of different treatment options, adequate symptom control is still one of the greatest challenges in the treatment of IBS.

Against this background, a combination of several different treatment approaches is usually recommended in guidelines. However, Haldeter et al. (10) found that even after 10 years of treatment, patients with IBS are still plagued by various kinds of symptoms. In addition, more than half of IBS primary care counseling is due to patients being dissatisfied with previous treatments (11). Indeed, there is evidence that patients often use numerous treatments (12).

Despite a broad spectrum of IBS treatment options, few data have been published so far on the subjective experience of engagement with these treatment modalities and their performance under actual clinical conditions. While the superiority of several different treatment modalities over placebo was supported by a multitude of clinical trials (13), there is only limited evidence (14) for which treatments patients are engaged in and which are experienced as helpful by patients. Therefore, the aims of this study were 1) to determine the individual usage of treatment modalities by IBS patients over time and 2) to assess the patients’ subjective experience of therapeutic impact.

MATERIALS AND METHODS

Study Design

This cross-sectional study was carried out at the Specialty Clinic for Functional Gastrointestinal Disorders at the Department of General Internal Medicine and Psychosomatics of Heidelberg University Hospital in tertiary care. This study was approved by the Ethics Committee of Heidelberg University (S-071/2017) and carried out in accordance with the Declaration of Helsinki and the Regulations for the Physicians of the Baden-Württemberg Chamber of Physicians in the latest versions. All patients who fulfilled the Rome III criteria for IBS and treated in our outpatient clinic between January 2012 and December 2016 were invited to the study. Patients received the study questionnaire package via mail, together with study invitation and consent forms, in October 2017. The study used the approach of the Dillman Total Design Method (15) to increase response rates.

There were 366 patients who fulfilled the Rome III criteria for IBS and thus were eligible for this study. Two hundred and four (55.7%) patients did not respond (including those whose new addresses were unknown), and three (0.8%) patients actively refused to participate in the study. Percentages of IBS subgroups, i.e., constipation predominant (IBS-C), diarrhea predominant (IBS-D), alternating or mixed (IBS-M), and undetermined (IBS-U), were also calculated in the patient cohort. The flowchart of patients’ responses and reasons for non-participation is shown in Figure 1.

Inclusion/exclusion criteria: All patients had to be ≥18 years of age and had to provide signed informed consent. Patients were only included if they fulfilled the Rome III criteria for the diagnosis of IBS (16). Patients with illiteracy were excluded.

Measures

In addition to the treatment modalities and the subjective experience of therapeutic impact, the sociodemographic data, symptom severity, psychological comorbidities, and quality of life were assessed by a set of general and functional gastrointestinal disorder–specific questionnaires.

Sociodemographic Data

Sociodemographic data including age, gender, family status, education level, duration of symptoms, and treatments were collected using the Psychosomatic Basis Documentation Questionnaire (Psy-BaDo) according to Heuft and Senf (17).

Symptomatic Characteristics

To assess the patients’ current symptomatic characteristics, symptom severity, quality of life, and psychological comorbidities were measured:

Symptom severity: Symptom severity was evaluated using the IBS Symptom Severity Scale (IBS-SSS, range 0–500) (18, 19). High values indicate greater symptom burden, and the following cutoff values have been suggested: <75 healthy, 75–174 mild, 175–300 moderate, and >300 severe IBS (20).

Quality of life: Quality of life was measured by the quality-of-life questionnaire for functional digestive disorders (FDDQL, range 0–100) (21, 22). FDDQL is a form of 48 items over eight domains (i.e., daily activity, disease-related anxiety, diet, sleep, discomfort, health perception, coping with disease, and impact of stress). Higher scores indicate better quality of life.

Psychological comorbidities: Depression was measured using the nine-item depression module of the Patient Health Questionnaire (PHQ-9, range 0–27) (23). A cutoff value of ≥10 was interpreted as clinically relevant depressive comorbidity. Anxiety was assessed using the Generalized Anxiety Disorder seven-item questionnaire (GAD-7, range 0–21) (24). A cutoff value of ≥10 was used to indicate clinically relevant anxiety comorbidity. Disease-related fear was measured with the brief Whitley Index-7 (WI-7, range 0–28) (25). A cutoff value of >3 was interpreted as the presence of a clinically relevant level of disease-related fear.

Usage of Treatment Modalities and Subjective Experience of Therapeutic Impact

To explore the usage of treatment modalities and patients’ subjective experience of therapeutic impact, an additional questionnaire set
was developed based on the German IBS treatment guidelines (9, 26) and the Patient Global Impression of Change (PGIC) scale (27).

To assess the individual usage of treatment modalities, participants were asked about their previous therapy experiences. Referring to the previous experience in this field (28), therefore, a structured and comprehensive list of different treatment modalities was developed. To develop this list, an initial focus group was employed. Next to the authors of the present work, the study involved 1) clinicians involved in the daily work with IBS patients, 2) clinical experts involved in the development of the German treatment guidelines for IBS, and 3) a methodologist. Based on the official German IBS guidelines (9, 26), an initial item pool was developed by this focus group, including all the treatment options generally recommended for IBS. This item pool was supplemented by various additional treatment options frequently reported by patients (e.g., complementary medicine, over-the-counter drugs). To assess the patients’ subjective experience of therapeutic impact for each treatment modality, we combined the treatment list with the seven-point Likert scale of the PGIC rating. Patients were asked to rate their subjective treatment satisfaction and global ratings of change of the overall situation using the following items: 1) very much improved, 2) much improved, 3) minimally improved, 4) no change, 5) minimally worse, 6) much worse, and 7) very much worse. Patients who rated PGIC with treatment as very much improved and much improved were treated as “improved”; minimally improved, no change, and minimally worse were treated as “non-response”; and very much worse and much worse were classified as “worsened” (29–31). After two rounds of piloting the comprehensibility, clarity, and comprehensiveness of this preliminary assessment, the treatment modalities were stratified according to five different treatment classes: non-specific general therapeutic recommendations (Cronbach’s α non-specific general therapeutic recommendations = 0.582, e.g., physical activity, herbal tea, symptom diary); dietary recommendations (Cronbach’s α dietary recommendations = 0.617, e.g., avoiding fructose, avoiding lactose, nutritional counseling); psychosocial interventions (Cronbach’s α psychosocial interventions = 0.669, e.g., abdominal hypnotherapy, relaxation therapy, stress management); symptom-targeting medications (Cronbach’s α symptom-targeting medications = 0.706, e.g., antidiarrhea drugs, antispasmodic drugs, acid inhibitor drugs); and complementary interventions (Cronbach’s α complementary interventions = 0.847, e.g., homoeopathy, manual therapy, integrative mind–body therapy). The Cronbach’s α overall coefficient in this study was 0.853.

**Statistical Analyses**

All statistical analyses were performed using IBM SPSS Statistics 22.0 for Windows. Partial correlation was used to assess the relationship between the number of treatment attempts and the PGIC score. The average PGIC score for all treatments ever used was used in the analysis. Additionally,
dropout analyses were performed to explore the impact of patients who completed the IBS diagnostic criteria at the initial visit but who dropped out in this study. For characterization of dropouts, data/medical records from the initial visit were used. All tests were two-sided. P-values less than 0.05 indicated statistical significance for all analyses. All analyses were explorative and not of a confirmatory nature; thus, no specific hypotheses were formulated.

RESULTS

Sociodemographic and Symptomatic Characteristics

The study could include 159 (43.4%) patients (43.7 ± 17.1 years of age; 71.1% female). Of the patient cohort, 47.8% were classified as IBS-D, 43.4% were classified as IBS-M, and 6.3% were classified as IBS-C. As shown in Table 1, the mean time since the first visit to the clinic was 2.8 ± 1.3 years (median 3.0 years). The mean time of symptom duration was 14.1 ± 11.1 years (median 10.0 years). The mean level of symptom severity of these patients was 225.5 ± 101.8. Of all patients, 48.4% reported scores at moderate severity levels, 9.4% showed scores above the cutoff of value for severe symptom severity, and 32.1% showed scores at mild severity levels. Categorizing participants according to the validated cutoff values, the prevalence was 16.1% for depressive syndrome, 27.6% for anxiety syndrome, and 44.9% for disease-related fear. When considering the subgroups of IBS, there was no significant differences among the demographic and clinical characteristics, subjective experience of therapeutic impact, and number of treatment attempts between IBS-D and IBS-M. For more details, see Table S1.

Usage of Treatment Modalities and Subjective Experience of Therapeutic Impact

Patients reported on average experiences with treatments from at least two different treatment classes. The most-often-used treatment classes were symptom-targeting medications (98.7%, 157) and non-specific general therapeutic recommendations (95.0%, 151). The least-used class was complementary treatments (46.5%, 74). The average number of treatment attempts by patients was 12, ranging from 2 to 39. The five most-often-used treatment modalities were 1) soluble fibers (e.g., psyllium seed husks); 2) herbal teas (e.g., fennel anise caraway tea); 3) physical activity; 4) hot-water bottle; and 5) liquid nine herbs (e.g., STW-5). For more details of the usage of treatment modalities within each class, see Figure 2.

With respect to the subjective experience of therapeutic impact, there were no significant differences in the PGIC scores among different treatments (p = 0.183). The rates of non-response (minimally improved, no change, or minimally worse) ranged from 63.0% to 83.9%. According to different treatment modalities, between 15% and 30% of all patients reported significant benefits (very much improved and much improved), and less than 5.0% reported that treatments have worsened their symptoms. For more details of the subjective experience of therapeutic impact within each class, see Figure 3. Table S2 of the Supplementary Material presents the top five of the different treatment modalities stratified according to usage rate and subjective experience of therapeutic impact. Figure S1 of the Supplementary Material presents the most-often-used treatments in general (treatments reported by <25% of the sample are not listed).

| TABLE 1 | Demographic characteristics, symptom burden, and quality of life of the study cohort. |
|----------|--------------------------------------------------------------------------------------|
| IBS patients (n = 159) |                                                    |
| Age | Mean ± SD (range) |
| | 43.4 ± 17.1 (18, 77) |
| Female | % (n) |
| | 71.1 (113) |
| Family status | % (n) |
| Single | 47.4 (63) |
| Stable cohabitation1 | 45.1 (60) |
| Divorced or widowed | 7.5 (10) |
| Education level above high school | % (n) |
| IBS subtypes | 72.6 (106) |
| IBS-C | 6.3 (10) |
| IBS-D | 47.8 (76) |
| IBS-M | 43.4 (69) |
| Number of treatment attempts | Median (range) |
| | 12 (2, 39) |
| First onset of symptoms in years | Mean ± SD |
| | 14.1 ± 11.1 |
| Clinic treatment period2 in years | Mean ± SD |
| | 2.8 ± 1.3 |
| Symptom severity (IBS-SSS) | Mean ± SD |
| | 225.5 ± 101.8 |
| Depression (PHQ-9) | Mean ± SD |
| | 5.4 ± 4.6 |
| Anxiety (GAD-7) | Mean ± SD |
| | 6.7 ± 5.0 |
| Disease-related fear (WI-7) | Mean ± SD |
| | 8.7 ± 6.5 |
| Quality of life (FDDQL) | Mean ± SD |
| | 56.8 ± 11.2 |

1Stable cohabitation, i.e., married/unmarried cohabitation. 2Clinic treatment period: the mean period of time since the first visit in the specialty care outpatient clinic and follow-up assessment.

IBS, irritable bowel syndrome; IBS-C, IBS with constipation; IBS-D, IBS with diarrhea; IBS-M, IBS with mixed bowel habits; IBS-SSS, IBS Symptom Severity Scale; GAD-7, Generalized Anxiety Disorder seven-item questionnaire; PHQ-9, nine-item depression module of the Patient Health Questionnaire; WI-7, brief Whitley Index-7; FDDQL, quality-of-life questionnaire for functional digestive disorders; SD, standard deviation.
Correlations Among the Subjective Experience of Impact, Number of Treatment Attempts, Symptom Severity, Psychological Comorbidities, and Quality of Life

The average PGIC score for all treatments ever used was used in the correlation analysis. Controlling the mean time of symptom duration and the mean period of time since the first visit, the PGIC score was correlated negatively with the mean number of treatment attempts ($r = -0.320$, $p < 0.01$). A similar relationship was found between PGIC score and the symptom severity ($r = -0.381$, $p < 0.01$). The mean number of treatment attempts also correlated negatively with quality of life ($r = -0.263$, $p < 0.01$). Depression, anxiety, and disease-related fear were all negatively correlated with PGIC score ($r = -0.354$, $-0.279$, $-0.257$, all $p < 0.01$). Meanwhile, depression and anxiety were both positively correlated with the number of attempted treatments ($r = 0.184$, $0.170$, all $p < 0.05$). For more details, see Table 2.

Dropout Analyses

Of the 207 dropouts, 67.1% (139) were female. The mean age was 36.8 ± 14.5 years (range 18–77 years). The study compared initial visit clinical questionnaire data between the...
participants who completed the study and those who dropped out. There were no statistically significant differences in regard to sociodemographic and symptomatic characteristics between participants and dropouts except the variables of age and IBS subtypes. For more details, see Table S3 of the Supplementary Material.

**DISCUSSION**

**Findings**

To our knowledge, this is the first study to evaluate specialty treatment practice variation among IBS patients at a tertiary care center in Germany. The study found that 1) IBS patients...
used an average of 12 different treatment modalities; 2) patients’ subjective experience of therapeutic impact (i.e., PGIC) scores with these treatments were characterized by high non-response rates, and there were no significant differences among different treatment modalities; and 3) the number of treatment attempts was negatively correlated with the subjective experience of therapeutic impact and the quality of life.

The most-often-used treatment classes in the study cohort were symptom-targeting medications (98.7%), such as soluble fibers (e.g., psyllium seed husks) and liquid nine herbs (e.g., STW-5), as well as non-specific general therapeutic recommendations (95.0%), such as physical activity and herbal teas (e.g., fennel anise caraway tea) for symptom reduction. This finding is in line with current guidelines, in which symptom-targeting medications are an important pillar for the treatment of IBS patients (9). As most patients suffer from more than one symptom, the use of numerous treatments is understandable. The treatments that patients in the study used are quite similar to those of a previous study from 2002 for the standard treatment of IBS (32). This study showed dietary advice, education, exercise advice, stress management and antispasmodic medications to be the most frequently used treatment modalities. This finding indicates that there have been no relevant changes in the medical care of IBS over the last 15 years.

In light of the unclear etiology of IBS and the resulting lack of causal therapies (33–35), it is not surprising that most patients use different treatment modalities. Accordingly, guidelines for the diagnosis and treatment of functional gastrointestinal diseases emphasize the combination of different therapies in a multimodal interdisciplinary treatment approach (8), including non-specific therapeutic recommendations as well as more specific recommendations, such as dietary advice, psychological interventions, and symptom-targeting medications. However, the number of treatment attempts with, on average, more than 12 different treatment modalities per patient was substantial in the study. In the face of this high number in combination with the high non-response rates, most treatments would be classified ineffective based on current clinical standards. Further, most treatment modalities were similar in terms of the perceived therapeutic impact. The rates of non-response were high in the study cohort, ranging on average from 63.0% to 83.9%. Most patients reported that previous treatments had hardly affected their symptoms so far. In line with this, almost two-thirds of the participants reported moderate to severe complaints and antispasmodic medications to be the most frequently used treatment modalities. This finding indicates that there have been no relevant changes in the medical care of IBS patients in our study showed meaningful levels of disease-associated with an exacerbated nocebo response (38). There were no significant relationships found when considering the correlation coefficient for PGIC number in non-specific general recommendations and psychosocial intervention. However, compared with other categories of treatment, psychosocial interventions and non-specific general recommendations are more susceptible to subjective conditions (e.g., cognition, personality, hypnosis), which means the responses to treatment vary more individually.

Although a high non-response rate was found, some mechanisms have also been reported. A possible mechanism to be discussed is the influence of previous negative treatment experiences on future therapy response. It is well known from nocebo research that negative expectations of a therapy have a strong potential to reduce future therapeutic effects (39). Given that the average IBS patient experiences a large number of frustrating therapy attempts, there is a risk that negative therapy expectations turn into a vicious cycle, with previous treatment failures leading to future treatment failures. Of note, anxiety was associated with an exacerbated nocebo response (40), and 44.9% of IBS patients in our study showed meaningful levels of disease-related fear, potentially indicating increased susceptibility to nocebo effects. However, these assumptions remain speculative, and further research is needed to better understand the underlying mechanisms.

Limitations and Strengths
Several limitations of this study should also be considered. First, this was a single-center study in tertiary care; our findings therefore may not be representative of practice at other centers or hospitals but instead may reflect our clinic’s experience. The study cohort represents the outpatient patients, with higher disease burden and more psychological comorbidities than the primary care sample. Thus, the findings cannot be generalized. However, this long-term study shows what the current IBS patients are facing. Second, not all the subjects could be followed up, although we used repeated mailings to lower the dropout rate. However, our response rate is similar to those of other studies in this field (41–43). Moreover, dropout analyses did not indicate any obvious selection bias, at least concerning sociodemographic and symptomatic characteristics. This study used a retrospective design to measure the relationship between the usage of treatment modalities and the subjective experience of therapeutic impact. Therefore, there is a risk of a potential bias associated with self-report only. In addition to random measurement error, self-reports may be systematically biased if respondents have imperfect recall or deliberately provide misleading answers (44). The resolution of risks, which might generate spurious positive or null findings, requires large sample sizes in the future. Third, we did not assess the data of dose, duration, frequency, or order of therapies, as they may limit the efficacy to some extent. Using less effective treatments first may increase symptom severity and the opportunity for developing psychosocial distress. However, this research gap in the field of treatment still needs to be focused on in the future.

Despite those limitations, the strengths of this study should not be neglected. First, the IBS diagnosis was confirmed by a medical examination. Moreover, the treatment modalities were
Conclusions and Implications

To conclude, the multidisciplinary treatment approach of IBS is characterized by high rates of non-response and frustrating treatment attempts. Overall, IBS imposes a substantial burden on patients. This study demonstrates a complex treatment reality that is characterized by various treatment attempts and frustrating subjective experience of therapeutic impact.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this manuscript will be made available by the authors, without undue reservation, to any qualified researcher. Requests for data should be sent to yuanjun.dong@med.uniheidelberg.de.

ETHICS STATEMENT

All subjects gave written informed consent in accordance with the Declaration of Helsinki. The protocol was approved by the Ethics Committee of Heidelberg University (S-071/2017).

AUTHOR CONTRIBUTIONS

The study concept and design were made by YD and JT. Acquisition of data was carried out by YD. Statistical analysis and interpretation of data were done by YD, DB, and SB. Drafting of the paper was done by YD. Critical revision of the content was by JT, DB, WE, and SB. WE was responsible for administrative or material support. Study supervision was held by JT.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpsyg.2019.00714/full#supplementary-material

FIGURE S1 | Subjective experience of therapeutic impact of the most often used treatments in general. Treatments reported by <25% of the sample are not listed; All values are shown as % (n); "Improved, patients who rated PGIC as very much improved or much improved; Non-response, patients who rated PGIC as minimally improved, no change or minimally worse; Worsened, patients who rated PGIC as very much worse or much worse; *Soluble fibres, e.g., psyllium seed husks; Herbal teas, e.g. fennel anise caraway tea; Liquid nine herbs, e.g., STW-5; Psychotherapy, e.g., cognitive behavioural therapy.

REFERENCES

1. Canavan C, West J, Card T. The epidemiology of irritable bowel syndrome. Clin Epidemiol (2014) 6:71–80. doi: 10.2147/CLEP.S40245
2. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol (2012) 10:712–21. e714. doi: 10.1016/j.cgh.2012.02.029
3. Agarwal N, Spiegel BM. The effect of irritable bowel syndrome on health-related quality of life and health care expenditures. Gastroenterol Clin (2011) 40:11–9. doi: 10.1016/j.gtc.2010.12.013
4. Canavan C, West J, Card T. The economic impact of the irritable bowel syndrome. Aliment Pharmacol Ther (2014) 40:1023–34. doi: 10.1111/apt.12938
5. Longstreth GF, Wilson A, Knight K, Wong J, Chiou C, Barghout V, et al. Irritable bowel syndrome, health care use, and costs: a US managed care perspective. Am J Gastroenterol (2003) 98:600–7. doi: 10.1016/S0002-9270(02)60618-5
6. Palsson OS, Baggish JS, Turner MJ, Whitehead WE. IBS patients show frequent fluctuations between loose/watery and hard/lumpy stools: implications for treatment. Am J Gastroenterol (2012) 107:286. doi: 10.1038/ajg.2011.358
7. Hauser G, Pletikosic S, Tkalcic M. Cognitive behavioral approach to understanding irritable bowel syndrome. World J Gastroenterol (2014) 20:6744. doi: 10.3748/wjg.v20.i22.6744
8. Drossman DA. Functional gastrointestinal disorders: history, pathophysiology, clinical features, and Rome IV. Gastroenterol (2016) 150:1262–79. e1262 doi: 10.1053/j.gastro.2016.02.032
9. Layer P, Andreassen V, Pehl C, Allescher H, Bischoof SC, Classen M, et al. Irritable bowel syndrome: German consensus guidelines on definition, pathophysiology and management. Z. Gastroenterol (2011) 49:237. doi: 10.3238/arztebl.2011.0751
10. Halder SL, Locke GR, III, Schleck CD, Zinsmeister AR, Melton LJ, Talley NJ. Natural history of functional gastrointestinal disorders: a 12-year longitudinal population-based study. Gastroenterology (2007) 133:799–807. doi: 10.1053/j.gastro.2007.06.010
11. Williams R, Black C, Kim HY, Andrews EB, Mangel AW, Bud JJ, et al. Determinants of healthcare-seeking behaviour among subjects with irritable bowel syndrome. Aliment Pharmacol Ther (2006) 23:1667–75. doi: 10.1111/j.1365-2036.2006.02928.x
12. Camilleri M, Di Lorenzo C. The brain–gut axis: from basic understanding to treatment of irritable bowel syndrome and related disorders. J Pediatr Gastroenterol Nutr (2012) 54:446. doi: 10.1097/MPG.0b013e31823d34c3
13. Ford AC, Moayyedi P, Lacy BE, Lembo AJ, Saito YA, Schaller LR, et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol (2014) 109:S2. doi: 10.1038/ajg.2014.187
14. Usai-Satta P, Bellini M, Lai M, Oppia F, Cabras F. Therapeutic approach for irritable bowel syndrome: old and new strategies.Curr Clin Pharmacol (2018) 13:164–172. doi: 10.2174/157488741366618070143606
15. Dillman DA. The importance of adhering to details of the Total Design Method (TDM) for mail surveys. New Dir Prog Eval (1984) 21:49–64. doi: 10.1002/ev.1359
16. Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology. (2006) 130:1377–90. doi: 10.1053/j.gastro.2006.03.008
17. Heuf G., Senff W. Practice of quality management in psychotherapy: manual for the Pay-BaDo [psychotherapeutic basis documentation]. Stuttgart, Germany: Thieme (1998). doi: 10.1007/0-0278050099
18. Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. *Aliment Pharmacol Ther* (1997) 11:395–402. doi: 10.1046/j.1365-2036.1997.142318000.x
19. Betz C, Mannsdörfer K, Bischoff S. Validation of the IBS-SSS. Z. Gastroenterol (2013) 51:1171–6. doi: 10.1055/s-0033-1335260
20. Saigo T, Tayama J, Ogawa S, Bernick PJ, Takeoaka A, Hayashida M, et al. Increased risk of irritable bowel syndrome in university students due to gastrointestinal symptom–specific anxiety. *Acta Medica Nagasakiensia* (2018) 61:137–43. doi: 10.1134/am.61.137
21. Chassany O, Marquis P, Scherrer B, Read NW, Finger T, Bergmann JF, et al. Validation of a specific quality of life questionnaire for functional digestive disorders. *Gut* (1999) 44:527–33. doi: 10.1136/gut.44.4.527
22. Yacavone RF, Locke GR III, Provenzale DT, Eisen GM. Quality of life measurement in gastroenterology: what is available? *Am J Gastroenterol* (2001) 96:285–97. doi: 10.1111/j.1572-0241.2001.00350.x
23. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. *J Gen Intern Med* (2001) 16:606–13. doi: 10.1046/j.1525-1497.2001.016009606.x
24. Spitzer RL, Kroenke K, Williams GB, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. *Arch Intern Med* (2006) 166:1092–7. doi: 10.1001/archinte.166.10.1092
25. Fink P, Ewald H, Jensen S, Sørensen L, Engberg M, Holm M, et al. Screening for somatization and hypochondriasis in primary care and neurological in-patients: a seven-item scale for hypochondriasis and somatization. *J Psychosom Res* (1999) 46:261–73. doi: 10.1016/S0022-3999(98)00092-0
26. Hausteiner-Wiehle C. Umgang mit Patienten mit nicht-spezifischen, funktionellen Krankheitserscheinungen: S3-Leitlinien mit Quellentexten, Praxismaterialien und Patientenleitlinie, Schattauer Verlag, 2013.
27. Geisser ME, Clauw DJ, Strand V, Gendreau RM, Palmer R, Williams D. A. Contributions of change in clinical status parameters to Patient Global Impression of Change (PGIC) scores among persons with fibromyalgia treated with milnacipran. *Pain* (2010) 149:373–8. doi: 10.1016/j.pain.2010.02.043
28. Berens S, Kraus F, Gauss A, Tesarz J, Herzog W, Niesler B, et al. A specialty clinic for functional gastrointestinal disorders in tertiary care: concept and patient population. *Clinical Gastroenterology and Hepatology*. *J Am Gastroenterol Assoc* (2017) 15:1127. doi: 10.1016/j.jgh.2017.02.039
29. Middel B, Stewart R, Bouma J, Sonderen E, Heuvel WJA. How to validate clinically important change in health-related functional status. Is the magnitude of the effect size consistently related to magnitude of change as indicated by a global question rating? *J Eval Clin Pract* (2001) 7:399–410. doi: 10.1046/j.1365-2753.2001.00298.x
30. Wyrwich KW, Nienaber NA, Tierney WM, Wolinsky FD. Linking clinical relevance and statistical significance in evaluating intra-individual changes indicated by a global question rating? *Am J Gastroenterol* (2004) 10:1305–15. doi: 10.1111/j.1572-0241.2004.02236.x
31. Floyd JA, Long JP Jr, Maloreaux I, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. *Pain* (2001) 94:149–58. doi: 10.1016/S0304-3959(01)00349-9
32. Whitehead WE, Levy RL, Von Korff M, Feld AD, Palsson OS, Turner M, et al. The usual medical care for irritable bowel syndrome. *Aliment Pharmacol Ther* (2004) 9:1014–25. doi: 10.1046/j.1365-2036.2004.02236.x
33. Halland M, Almazar A, Lee R, Atkinson E, Larson J, Talley NJ, et al. A case–control study of childhood trauma in the development of irritable bowel syndrome. *Neurogastroenterol Motility* (2014) 26:990–8. doi: 10.1111/nmo.12353
34. Barbara G, Feinle-Bisset C, Ghoshal UC, Quigley EM, Santos J, Vanner S, et al. The intestinal microenvironment and functional gastrointestinal disorders. *Gastroenterology* (2016) 150:1305–18. doi: 10.1053/j.gastro.2016.02.028
35. Shanahan F, Quigley EM. Manipulation of the microbiota for treatment of IBS and IBD—challenges and controversies. *Gastroenterology* (2014) 146:1534–63. doi: 10.1053/j.gastro.2014.01.052
36. Dapogny M, Bellanger J, Bonaz B, Bruley des Varannes S, Bueno L, Coffin R, et al. Irritable bowel syndrome in France: a common, debilitating and costly disorder. *Eur J Gastroenterol Hepatol* (2004) 16:995–1001. doi: 10.1097/00042737-200410000-00008
37. Mujagic Z, Ludidi S, Keszthelyi D, Hesslerink MA, Kruimel JW, Lenaerts K, et al. Small intestinal permeability is increased in diarrhea predominant IBS, while alterations in gastroduodenal permeability in all IBS subtypes are largely attributable to confounders. *Aliment Pharmacol Ther* (2014) 40:288–97. doi: 10.1111/apt.12829
38. Gazouli M, Wouters MM, Kapur-Pojskic L, Bengtson MB, Friedman E, Nikolovic G, et al. Lessons learned—resolving the enigma of genetic factors in IBS. *Nat Rev Gastroenterol Hepatol* (2016) 13:77. doi: 10.1038/nrgastro.2015.206
39. Enck P, Benedetti F, Schedlowski M. New insights into the placebo and nocebo responses. *Neurotox* (2008) 59:195–206. doi: 10.1016/j.neuron.2008.06.030
40. Staats PS, Staats A, Hekmat H. The additive impact of anxiety and a placebo on pain. *Pain Med* (2001) 2:267–79. doi: 10.15264/j.1526-4637.2001.01046.x
41. Zernicke KA, Campbell TS, Bluestein PK, Fung TS, Johnson JA, Bacon SL, et al. Mindfulness-based stress reduction for the treatment of irritable bowel syndrome symptoms: a randomized wait-list controlled trial. *Int J Behav Med* (2013) 20:385–96. doi: 10.1016/j.ijbem.2012.09.001
42. Abdul-Baki H, El Hajj II, Elzahabi L, Azar C, Aoun E, Skoury A, et al. A randomized controlled trial of imipramine in patients with irritable bowel syndrome. *World J Gastroenterol* (2009) 15:3636. doi: 10.3748/wjg.15.3636
43. Mazzawi T, Hausken T, Gunderson D, El-Sally M. Effect of dietary management on the gastric endocrine cells in patients with irritable bowel syndrome. *Eur J Clin Nutr* (2015) 69:519. doi: 10.1038/ejcn.2014.151
44. Bauhöft S. Systematic self-report bias in health data: impact on estimating cross-sectional and treatment effects. Health Serv Outcomes Res Methodol (2011) 11:44–53. doi: 10.1007/s11745-011-0069-3
45. Törnblom H, Goosey R, Wiseman G, Baker S, Emmanuel A. Understanding symptom burden and attitudes to irritable bowel syndrome with diarrhoea: results from patient and healthcare professional surveys. *United Eur Gastroenterol J* (2018) 6:1417–27. doi: 10.1177/2050640618787648

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

*Copyright © 2019 Dong, Baumester, Berens, Eich and Tesarz. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*